Every Form 4 that Journey Medical Corporation (DERM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DERM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DERM filings page.
Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Toledano Miranda Jayne received a grant of 50,000 shares of common stock in the form of restricted stock units on July 1, 2026 under the company’s 2015 Stock Plan. These RSUs vest in three annual installments: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030, and 16,667 shares on July 1, 2031.
Following this award, Toledano directly holds 168,618 shares of Journey Medical common stock, including restricted stock units that vest over various time periods. The grant reflects equity-based compensation rather than an open-market purchase.
Smith Justin Adam reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Justin Adam Smith received a grant of 50,000 restricted stock units as equity compensation. The award was granted on July 1, 2026 under Journey Medical Corp's 2015 Stock Plan, as amended. These restricted stock units vest over a long-term schedule: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030 and 16,667 shares on July 1, 2031, tying the director’s compensation to the company’s future performance. Following this grant, Smith directly holds a total of 231,618 shares and restricted stock units, which vest over various time periods.
Herskowitz Neil reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Neil Herskowitz received a grant of 50,000 restricted stock units (RSUs) of common stock as equity compensation. The grant was made on July 1, 2026 under the company’s 2015 Stock Plan and will vest over several years.
The RSUs vest in three tranches: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030, and 16,667 shares on July 1, 2031, if applicable conditions are met. After this award, Herskowitz’s direct holdings, including RSUs that vest over time, total 168,618 shares.
Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Miranda Jayne Toledano received an equity award of 10,000 shares of common stock in the form of restricted stock units. The grant was made on June 25, 2026 under the company’s 2015 Stock Plan, as amended.
The 10,000 restricted stock units are scheduled to vest in full on June 25, 2027, increasing her time-based incentive to remain aligned with shareholders. After this grant, Toledano’s direct holdings, including other restricted stock units that vest over various periods, total 118,618 shares of Journey Medical common stock.
Smith Justin Adam reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Justin Adam Smith received a grant of 10,000 shares of common stock as restricted stock units on June 25, 2026. These units were issued under the company’s 2015 Stock Plan and will vest as 10,000 shares on June 25, 2027.
After this equity award, Smith’s direct holdings total 181,618 shares, including restricted stock units that vest over various time periods. This is a compensation-related equity grant rather than an open-market share purchase or sale.
Herskowitz Neil reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Neil Herskowitz received a grant of 10,000 restricted stock units as equity compensation. The award was made under the company’s 2015 Stock Plan and will vest in full on June 25, 2027. Following this grant, Herskowitz’s direct holdings total 118,618 shares, including restricted stock units that vest over various periods.
Pearce Michael Cooper reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Michael Cooper received a grant of 10,000 restricted stock units (RSUs). The award, granted on June 25, 2026 under the company’s 2015 Stock Plan, will vest in full as 10,000 shares on June 25, 2027. After this grant, Cooper directly holds 67,173 shares of Journey Medical common stock, including RSUs that vest over various time periods.
ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Lindsay A. Rosenwald, M.D. reported an equity compensation award rather than an open-market trade. On June 25, 2026, he was granted 10,000 restricted stock units that are scheduled to vest as 10,000 shares on June 25, 2027.
After this award, his direct holdings of common stock, including restricted stock units that vest over various periods, total 221,146 shares. A separate entry shows 176,470 shares held indirectly through a limited liability company over which he, as managing member, is deemed to have voting and investment power.
Journey Medical Corp Chief Operating Officer Ramsey Alloush received new equity awards as part of compensation. On April 22, 2026, he was granted 46,863 restricted stock units that vest in three equal installments on April 22 of 2027, 2028, and 2029. He also received stock options for 62,795 shares of common stock at an exercise price of $5.04 per share, vesting on the same dates. After these awards, he directly owns 598,543 shares of common stock, including restricted stock units. The options expire on April 22, 2036, giving him long-term upside exposure tied to the company’s share price.
Journey Medical Corp CFO Joseph Benesch received new equity awards as part of his compensation. On April 22, 2026, he was granted 28,907 restricted stock units that vest in three annual installments from April 2027 through April 2029. He also received 41,860 stock options with an exercise price of $5.04 per share, vesting annually over the same three-year period and expiring in 2036. After these awards, he directly holds 261,371 shares of common stock, and has 41,860 options outstanding.
Journey Medical Corp reported that President & CEO Claude Maraoui received new equity awards as part of his compensation. On April 22, 2026, he was granted 49,277 restricted stock units that vest in three equal annual installments from 2027 through 2029.
He was also granted stock options for 82,915 shares at an exercise price of $5.04 per share, vesting on the same 2027–2029 schedule and expiring in 2036. Following these grants, Maraoui directly holds 2,435,990 shares of common stock and 82,915 options.